Karen Kaschak
Psychiatric/Mental Health · Cape May Court House, NJNPI 1013078906
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$924
- Alkermes, Inc.$873
- Neurocrine Biosciences, Inc.$871
- AbbVie$807
- Lundbeck LLC$773
- Teva Pharmaceuticals USA, Inc.$766
- plus $2K from 14 others
What the payments were for
- Food & beverage$6,99496%
- Education$3044%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $924 |
| Alkermes, Inc. | 51 | $873 |
| Neurocrine Biosciences, Inc. | 54 | $871 |
| AbbVie | 69 | $807 |
| Lundbeck LLC | 63 | $773 |
| Teva Pharmaceuticals USA, Inc. | 50 | $766 |
| Otsuka America Pharmaceutical, Inc. | 31 | $540 |
| Johnson & Johnson | 15 | $286 |
| E.r. Squibb & Sons, L.L.C. | 17 | $251 |
| Axsome Therapeutics, Inc. | 15 | $251 |
| Sunovion Pharmaceuticals Inc. | 10 | $223 |
| Vanda Pharmaceuticals Inc. | 16 | $217 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| ANI Pharmaceuticals, Inc. | 1 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $87 |
| Indivior Inc. | 6 | $87 |
| Corium, LLC | 4 | $60 |
| Braeburn Inc. | 1 | $15 |
| Tris Pharma Inc | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$492
- CAPLYTA$128
- INGREZZA$127
- PURIFIED CORTROPHIN GEL$115
How this compares
$7,299 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 65 | $344,155 |
| Invega SustennaPaliperidone Palmitate | 56 | $200,160 |
| IngrezzaValbenazine Tosylate | 23 | $193,801 |
| VraylarCariprazine Hcl | 63 | $99,169 |
| RexultiBrexpiprazole | 40 | $77,099 |
| TrintellixVortioxetine Hydrobromide | 89 | $45,923 |
| LybalviOlanzapine/Samidorphan Malate | 29 | $44,141 |
| CaplytaLumateperone Tosylate | 19 | $43,250 |
| Lurasidone Hcl | 106 | $39,955 |
| PerserisRisperidone | 13 | $36,890 |
| Aripiprazole | 269 | $35,182 |
| Bupropion XlBupropion Hcl | 257 | $11,693 |
| Quetiapine Fumarate | 448 | $10,730 |
| Effexor XrVenlafaxine Hcl | 12 | $8,950 |
| Divalproex Sodium ErDivalproex Sodium | 167 | $8,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $766 | $344,15565 claims |
| Johnson & JohnsonInvega Sustenna | $286 | $200,16056 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $871 | $193,80123 claims |
| AbbVieVraylar | $807 | $99,16963 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $540 | $77,09940 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $87 | $45,92389 claims |
| Alkermes, Inc.Lybalvi | $873 | $44,14129 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $924 | $43,25019 claims |
| Indivior Inc.Perseris | $87 | $36,89013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Cape May Court House
- Ubong UdofiaMarlton$407K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.